R&G PharmaStudies Co., Ltd. (SHE:301333)

China flag China · Delayed Price · Currency is CNY
63.47
-2.36 (-3.58%)
At close: Apr 29, 2026
43.40%
Market Cap 6.09B
Revenue (ttm) 896.26M
Net Income (ttm) 133.65M
Shares Out 95.99M
EPS (ttm) 1.40
PE Ratio 45.29
Forward PE 36.69
Dividend 0.16 (0.24%)
Ex-Dividend Date Jul 8, 2025
Volume 1,460,440
Average Volume 2,416,680
Open 65.29
Previous Close 65.83
Day's Range 63.41 - 65.60
52-Week Range 43.05 - 91.78
Beta 0.70
RSI 47.07
Earnings Date Apr 28, 2026

About R&G PharmaStudies

R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services. It serves pharmaceutical and medical device companies, and scientific research institutions. The company was founded in 2008 and is headquarter... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 2,645
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301333
Full Company Profile

Financial Performance

In 2025, R&G PharmaStudies's revenue was 851.01 million, an increase of 14.38% compared to the previous year's 744.00 million. Earnings were 136.90 million, a decrease of -2.37%.

Financial Statements

News

There is no news available yet.